The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mevalonate pathway inhibitors in the treatment of B-cell chronic lymphocytic leukemia.
Ravi Kiran Bobba
No relevant relationships to disclose
Indira Benakanakere
No relevant relationships to disclose
Smitha Bearelly
No relevant relationships to disclose
Monica Arya
No relevant relationships to disclose
Richard Sleigtholm
No relevant relationships to disclose
Carl Freter
No relevant relationships to disclose